These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20223922)

  • 1. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
    Giuriato S; Foisseau M; Dejean E; Felsher DW; Al Saati T; Demur C; Ragab A; Kruczynski A; Schiff C; Delsol G; Meggetto F
    Blood; 2010 May; 115(20):4061-70. PubMed ID: 20223922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.
    Lamant L; Dastugue N; Pulford K; Delsol G; Mariamé B
    Blood; 1999 May; 93(9):3088-95. PubMed ID: 10216106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
    Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
    Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
    Giuriato S; Faumont N; Bousquet E; Foisseau M; Bibonne A; Moreau M; Al Saati T; Felsher DW; Delsol G; Meggetto F
    Cancer Biol Ther; 2007 Aug; 6(8):1318-23. PubMed ID: 17660712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
    Dejean E; Renalier MH; Foisseau M; Agirre X; Joseph N; de Paiva GR; Al Saati T; Soulier J; Desjobert C; Lamant L; Prósper F; Felsher DW; Cavaillé J; Prats H; Delsol G; Giuriato S; Meggetto F
    Leukemia; 2011 Dec; 25(12):1882-90. PubMed ID: 21778999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
    Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
    Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases.
    Onciu M; Behm FG; Downing JR; Shurtleff SA; Raimondi SC; Ma Z; Morris SW; Kennedy W; Jones SC; Sandlund JT
    Blood; 2003 Oct; 102(7):2642-4. PubMed ID: 12816858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice.
    Merz H; Kaehler C; Hoefig KP; Branke B; Uckert W; Nadrowitz R; Cerny-Reiterer S; Herrmann H; Feller AC; Valent P
    Oncotarget; 2010 Jun; 1(2):104-119. PubMed ID: 21297223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
    Cussac D; Greenland C; Roche S; Bai RY; Duyster J; Morris SW; Delsol G; Allouche M; Payrastre B
    Blood; 2004 Feb; 103(4):1464-71. PubMed ID: 14563642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
    Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
    Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G
    Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma.
    Li C; Takino H; Eimoto T; Ishida T; Inagaki A; Ueda R; Suzuki R; Yoshino T; Nakagawa A; Nakamura S; Inagaki H
    Mod Pathol; 2007 Jun; 20(6):648-55. PubMed ID: 17464320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK
    Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM
    Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo.
    Coluccia AM; Perego S; Cleris L; Gunby RH; Passoni L; Marchesi E; Formelli F; Gambacorti-Passerini C
    Blood; 2004 Apr; 103(7):2787-94. PubMed ID: 14656879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.
    Wan W; Albom MS; Lu L; Quail MR; Becknell NC; Weinberg LR; Reddy DR; Holskin BP; Angeles TS; Underiner TL; Meyer SL; Hudkins RL; Dorsey BD; Ator MA; Ruggeri BA; Cheng M
    Blood; 2006 Feb; 107(4):1617-23. PubMed ID: 16254137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
    Laimer D; Dolznig H; Kollmann K; Vesely PW; Schlederer M; Merkel O; Schiefer AI; Hassler MR; Heider S; Amenitsch L; Thallinger C; Staber PB; Simonitsch-Klupp I; Artaker M; Lagger S; Turner SD; Pileri S; Piccaluga PP; Valent P; Messana K; Landra I; Weichhart T; Knapp S; Shehata M; Todaro M; Sexl V; Höfler G; Piva R; Medico E; Ruggeri BA; Cheng M; Eferl R; Egger G; Penninger JM; Jaeger U; Moriggl R; Inghirami G; Kenner L
    Nat Med; 2012 Nov; 18(11):1699-704. PubMed ID: 23064464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
    Ouyang T; Bai RY; Bassermann F; von Klitzing C; Klumpen S; Miething C; Morris SW; Peschel C; Duyster J
    J Biol Chem; 2003 Aug; 278(32):30028-36. PubMed ID: 12748172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Anand M; Lai R; Gelebart P
    Haematologica; 2011 Feb; 96(2):253-61. PubMed ID: 20971814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.